Spotlight On... Mylan gets one step closer to finally challenging Glaxo's Advair; Mylan appoints new commercial chief; Amgen, UCB osteoporosis contender shines in postmenopausal patients; and more...

Generic competition to GlaxoSmithKline ($GSK) respiratory behemoth Advair could finally be on the horizon, and Mylan ($MYL) wants to make sure it gets a piece of the med's blockbuster revenues. Friday, the company announced that the FDA had accepted its application for a copy of the blockbuster, with a decision date set for the end of March. Mylan joins Hikma and Novartis' ($NVS) Sandoz, which have already made FDA submissions. Release

> Mylan ($MYL) has appointed Anthony Mauro as its new chief commercial officer. Release

> Amgen ($AMGN) and UCB's osteoporosis candidate, romosozumab, showed in a late-stage study that it could reduce the incidence of new vertebral fracture in postmenopausal patients with the disease. Report

> Endo ($ENDP) has launched Belbuca buccal film, a treatment for chronic pain management. Release

> Merck KGaA has launched its "More Than a Mother" campaign in partnership with Uganda's health ministry to raise awareness about preventing infertility in the country. Report

And Finally... Spending more on government-sponsored drug studies could encourage label expansions and cut down on off-label marketing. More

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The U.S. aesthetics business is booming with fillers and fat freezers garnering interest, and spurring marketing campaigns, post-lockdown COVID-19.